目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T61451 | |||
NMDAR/HDAC-IN-1 (Compound 9d) is a potent dual inhibitor of N-methyl-D-aspartate receptors (NMDARs) and histone deacetylases (HDACs). It exhibits a high affinity (Ki = 0.59 μM) for NMDARs, while demonstrating significant inhibitory effects on various HDAC isoforms, including HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 with IC 50 values of 2.67 μM, 8.00 μM, 2.21 μM, 0.18 μM, and 0.62 μM, respectively. Moreover, NMDAR/HDAC-IN-1 efficiently crosses the blood-brain barrier [1]. | |||
T63664 | |||
CDK/HDAC-IN-2 是有效的 HDAC/CDK 双重抑制剂,能够作用于 HDAC1 (IC50: 6.4 nM)、HDAC2 (IC50: 0.25 nM)、HDAC3 (IC50: 45 nM)、HDAC6,8 (IC50>1000 nM)、CDK1 (IC50: 8.63 nM)、CDK2 (IC50: 0.30 nM)、CDK4,6,7 (IC50>1000 nM)。CDK/HDAC-IN-2 能够将细胞周期停滞在 G2/M 期,并诱导细胞凋亡 (apoptosis)。CDK/HDAC-IN-2 具有优异的抗增殖效果,显示出显著的抗肿瘤作用。 | |||
T4481 | HDAC | ||
Tucidinostat (Chidamide) 是一种可口服的 HDAC I 类 HDAC1/2/3和第 IIb 类 HDAC10的抑制剂,IC50值分别为 95、160、67 和 78 nM。 | |||
T36629 | |||
Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1β secretion more than 70%. Givinostat (ITF-2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 100 and 200 nM, there is no reduction[1]. As shown by the CCK-8 assay, Givinostat (ITF-2357) inhibits JS-1 cell proliferation in a concentration-dependent manner. Treatment with Givinostat ≥500 nM is associated with significant inhibition of JS-1 cell proliferation (P<0.01). Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat ≥250 nM plus LPS and the group without LPS treatment (same Givinostat concentration) (P<0.05)[2]. Givinostat (ITF2357) at 10 mg/kg is used as a positive control and, as expected, reduced serum TNFα by 60%. Strikingly, pretreatment of ITF3056 starting at 0.1 mg/kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg/kg), and blood is collected after 4 h. Similarly, when pretreated with lower doses of Givinostat (ITF-2357) (1 or 5 mg/kg), there is a 22% reduction for 1 mg/kg and 40% for 5 mg/kg[1]. [1]. Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78. [2]. Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39. [3]. Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15. | |||
T79683 | Others | ||
HDAC/CD13-IN-1 (Compound 12) 作为HDAC/CD13抑制剂, 对hCD13的IC50为0.34 μM, 猪CD13为0.53 μM, 对HDAC1/2/3的IC50分别为0.03、0.06、0.02 μM。此化合物有效抑制MV4-11、K562、Jeko-1 和 HL60细胞增殖, IC50范围为0.25-2.04 μM,并诱导癌细胞凋亡。同时表现出抗转移和抗侵袭的特性。 | |||
T73515 | Apoptosis HDAC | ||
MC2590 是一种具有有效性和选择性的组蛋白脱乙酰酶 (HDAC) 抑制剂 ,抑制 HDAC1-3、-6、-8 和 -10 的活性,诱导细胞周期停滞,促进细胞凋亡。 | |||
T14947 | HDAC | ||
CHDI-390576 是一种具有中枢神经系统渗透性、选择性和高效性的二苯甲酰异羟肟酸 IIa 类组蛋白脱乙酰酶(HDAC) 抑制剂,抑制 IIa 类 HDAC 4、HDAC 5、HDAC 7、HDAC 9 ,可用于研究癌症。 | |||
T16962 | HDAC | ||
SW-100 是一种选择性组蛋白去乙酰化酶 6 抑制剂,IC50为2.3 nM。它有提高的穿过血脑屏障的能力,相对于其他 HDAC 同工酶,还显示出对 HDAC6 的至少高 1000 倍的选择性。 | |||
T24764 | |||
SB-429201 is an effective, selective inhibitor of HDAC1. | |||
T23821 | |||
BRD4884 is a selective inhibitor of HDAC2 that acts by enhancing the learning and memory processes. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-01473 | HDAC3 Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
HDAC3 Protein, Human, Recombinant (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 64.8 kDa and the accession number is O15379.
|
|||||
TMPY-03431 | HDAC4 Protein, Human, Recombinant (aa 612-1084) | Human | Baculovirus Insect Cells | ||
HDAC4 (histone deacetylase 4), belongs to class II of the histone deacetylase/AcuC/APhA family. Histone Deacetylases (HDACs) are a group of enzymes closely related to sirtuins. They catalyze the removal of acetyl groups from lysine residues in histones and non-histone proteins, resulting in transcriptional repression. In general, they do not act autonomously but as components of large multiprotein complexes, such as pRb-E2F and mSin3A, that mediate important transcription regulatory pathways. There are three classes of HDACs; classes 1, 2, and 4, which are closely related to Zn2+-dependent enzymes. HDACs are ubiquitously expressed and they can exist in the nucleus or cytosol. Their subcellular localization is affected by protein-protein interactions and by the class to which they belong. HDACs have a role in cell growth arrest, differentiation, and death and this has led to substantial interest in HDAC inhibitors as possible antineoplastic agents. HDAC4 possesses histone deacetylase activity and represses transcription when tethered to a promoter. It does not bind DNA directly but through transcription factors MEF2C and MEF2D. HDAC4 seems to interact in a multiprotein complex with RbAp48 and HDAC3.
|